Roche has released new data from its Phase III FENtrepid trial demonstrating that fenebrutinib, an investigational Bruton’s tyrosine kinase (BTK) inhibitor, met its primary goal of being at least as effective as ocrelizumab (Ocrevus) in reducing disability progression in patients with primary progressive multiple sclerosis (PPMS). The study showed a 12% reduction in the risk of disability worsening compared to ocrelizumab, the current standard treatment for PPMS, with benefits observed as early as 24 weeks into treatment.
The effect of fenebrutinib was consistent across different patient groups throughout the study duration, indicating a stable impact on slowing disease progression.
**Why this matters**
PPMS is a form of multiple sclerosis characterized by gradual worsening of neurological function, and treatment options have been limited. Fenebrutinib represents the first investigational therapy in over ten years to demonstrate a reduction in disability progression in this patient population, potentially offering a new therapeutic option for those affected by this challenging condition.
Source: NewsData